SG11201600076WA - LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME - Google Patents
LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAMEInfo
- Publication number
- SG11201600076WA SG11201600076WA SG11201600076WA SG11201600076WA SG11201600076WA SG 11201600076W A SG11201600076W A SG 11201600076WA SG 11201600076W A SG11201600076W A SG 11201600076WA SG 11201600076W A SG11201600076W A SG 11201600076WA SG 11201600076W A SG11201600076W A SG 11201600076WA
- Authority
- SG
- Singapore
- Prior art keywords
- sirna
- double
- preventing
- composition
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130080579A KR20150006742A (ko) | 2013-07-09 | 2013-07-09 | 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
| PCT/KR2014/006145 WO2015005669A1 (en) | 2013-07-09 | 2014-07-09 | LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201600076WA true SG11201600076WA (en) | 2016-02-26 |
Family
ID=52280271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201600076WA SG11201600076WA (en) | 2013-07-09 | 2014-07-09 | LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160168573A1 (enExample) |
| EP (1) | EP3019611A4 (enExample) |
| JP (1) | JP2016531563A (enExample) |
| KR (1) | KR20150006742A (enExample) |
| CN (1) | CN105765069A (enExample) |
| SG (1) | SG11201600076WA (enExample) |
| WO (1) | WO2015005669A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116898870A (zh) * | 2017-07-28 | 2023-10-20 | 雷莫内克斯生物制药有限公司 | 用于预防或治疗肝癌的药物组合物 |
| CN110964816A (zh) * | 2019-11-20 | 2020-04-07 | 深圳市鲲鹏未来科技有限公司 | 包含血液稳定性纳米颗粒的溶液、其制备方法及miRNA标志物的检测方法 |
| CN111189808B (zh) * | 2019-12-25 | 2022-12-06 | 宁夏医科大学总医院 | 与肝脏损伤、肝细胞凋亡相关特异蛋白分子标志物筛选方法 |
| CN111596059A (zh) * | 2020-05-19 | 2020-08-28 | 上海长海医院 | Gankyrin蛋白作为新型分子标志物在前列腺癌预后评估中的应用 |
| KR102329524B1 (ko) * | 2021-08-06 | 2021-11-23 | 주식회사 네오나 | 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물 |
| WO2023013818A1 (ko) * | 2021-08-06 | 2023-02-09 | 주식회사 네오나 | 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물 |
| CA3267582A1 (en) * | 2022-09-28 | 2024-04-18 | Ohio State Innovation Foundation | RNA NANOSTRUCTURES AND COMPLEXES FOR THE TREATMENT OF CANCER METASTASES |
| CN117281792A (zh) * | 2023-07-25 | 2023-12-26 | 浙江大学 | 一种用于增强肝癌免疫疗法治疗效果的纳米制剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2950520B2 (ja) * | 1993-04-02 | 1999-09-20 | アンティキャンサー インコーポレーテド | 毛胞に有益な配合物を送達する方法 |
| WO2006006948A2 (en) * | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
| EP2213738B1 (en) * | 2002-11-14 | 2012-10-10 | Dharmacon, Inc. | siRNA molecules targeting Bcl-2 |
| AU2005292083A1 (en) * | 2004-09-29 | 2006-04-13 | Alza Corporation | Microparticles and nanoparticles containing a lipopolymer |
| JP2010515771A (ja) * | 2007-01-16 | 2010-05-13 | プロテオロジクス リミテッド | トポイソメラーゼインヒビターの治療効果を増強する方法 |
| KR101224828B1 (ko) * | 2009-05-14 | 2013-01-22 | (주)바이오니아 | siRNA 접합체 및 그 제조방법 |
| EP2496268A4 (en) * | 2009-11-06 | 2013-06-19 | Univ Chung Ang Ind | GENERATING SYSTEMS ON NANOPARTICLE BASIS |
| JP5952423B2 (ja) * | 2011-12-15 | 2016-07-13 | バイオニア コーポレーションBioneer Corporation | 新規オリゴヌクレオチド接合体およびその用途 |
-
2013
- 2013-07-09 KR KR20130080579A patent/KR20150006742A/ko not_active Withdrawn
-
2014
- 2014-07-09 WO PCT/KR2014/006145 patent/WO2015005669A1/en not_active Ceased
- 2014-07-09 EP EP14822311.8A patent/EP3019611A4/en not_active Withdrawn
- 2014-07-09 SG SG11201600076WA patent/SG11201600076WA/en unknown
- 2014-07-09 US US14/902,808 patent/US20160168573A1/en not_active Abandoned
- 2014-07-09 JP JP2016525279A patent/JP2016531563A/ja not_active Withdrawn
- 2014-07-09 CN CN201480048986.8A patent/CN105765069A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016531563A (ja) | 2016-10-13 |
| CN105765069A (zh) | 2016-07-13 |
| EP3019611A4 (en) | 2017-06-14 |
| KR20150006742A (ko) | 2015-01-19 |
| EP3019611A1 (en) | 2016-05-18 |
| US20160168573A1 (en) | 2016-06-16 |
| WO2015005669A1 (en) | 2015-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201600076WA (en) | LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME | |
| EP3019612A4 (en) | LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME | |
| LT3365373T (lt) | Surišančios molekulės, kurios inhibuoja vėžio augimą | |
| EP3326661B8 (en) | Bio-ink composition having improved physical and biological properties | |
| IL243752B (en) | Multispecific antibodies, preparations containing them and their uses | |
| IL241055A (en) | Transgenic liver tissue, their arrays and methods of preparation | |
| PL2818483T3 (pl) | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi | |
| PL2986304T3 (pl) | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania | |
| EP4592397A3 (en) | Biosensor microarray compositions and methods | |
| IL245839B (en) | Inhibitors of rna polymerase i and use of preparations containing them for treatment | |
| PL3355913T3 (pl) | Cząsteczki wiążące ze zmodyfikowanym łańcuchem j | |
| IL241823B (en) | Preparations containing novyi .c and their uses for the treatment of cancerous tumors | |
| EP3085784A4 (en) | Nucleic acid inducing rna interference modified for preventing off-target, and use thereof | |
| PT3272874T (pt) | Composição de reagente para biossensor e biossensor tendo a mesma | |
| EP3052510A4 (en) | Methods and compositions for treating and/or preventing mucositis | |
| EP3077049A4 (en) | Compositions and methods for treating vitiligo | |
| EP3085380A4 (en) | Composition for treating prostate cancer | |
| EP3390378A4 (en) | SMALL MOLECULES AGAINST CANCER | |
| EP3052122A4 (en) | Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma | |
| ZA202001649B (en) | Rna molecules | |
| BR112015002729A2 (pt) | composição de revestimento, artigo, e, método. | |
| HK1225630A1 (zh) | 小分子c-myc抑制劑 | |
| ZA201802618B (en) | Anti-cd43 antibody and use thereof for cancer treatment | |
| EP3020399A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER | |
| EP3181139A4 (en) | Composition for preventing or treating cervical cancer including gypenoside lxxv |